← Leaderboards
Creinin Michael
University Of California At Davis
$1,079,384
Attributed
$1,079,384
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $381.5K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,079,384 · 1
By mechanism
N01$1,079,384 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California At Davis
Same institution · by research overlap
- Kc Kent Lloyd$119,085,810
- Laura Marcu$16,612,855
- Charles Decarli$84,485,572
- Mitchell Creinin$1,262,223
- Richard M. Levenson$15,762,754
Others in their field
Other Emerging Leaders on “Adherence”
- Kimberly Smith · Ppd Development Lp$115,671,664
- Martha Hering · Westat, Inc.$57,098,843
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Susan M Landau · University Of California Berkeley$47,252,026
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Priyamvada Acharya · Duke University$20,941,151
Research focus
AdherenceClinical Practice GuidelineClinical TrialsClinical Trials NetworkContraceptive AgentsContraceptive EfficacyContraceptive MethodsContractorDoseDrug KineticsEnrollmentEstrogensEvaluationFemale Contraceptive AgentsFollow-UpFree WillGood Clinical PracticeGovernmentImplantInjectableInjectionsInternationalIntramuscularIntrauterine Devices
Grant awards (6)
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION - UC DAVIS$35,949
N01 · FY2025 · HD · contact PI
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION - UC DAVIS$381,546
N01 · FY2024 · HD · contact PI
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION$103,109
N01 · FY2023 · HD · contact PI
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION$125,855
N01 · FY2022 · HD · contact PI
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION$175,964
N01 · FY2021 · HD · contact PI
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION$256,961
N01 · FY2018 · HD · contact PI